Bioventus Inc. (BVS) bonds
BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value
$10.66−0.20 (-1.84%)
Close on Nov 13, 2026Market cap $896.42MP/E 13.3Yield –
Debt
Borrowings on the balance sheet, Sep 26, 2026
Total debt
$229.83M
$18.75M due within a year
Net debt
$199.12M
After $30.71M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2024
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Bioventus's 10-Q for the period ended Jun 27, 2026
Bioventus's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Available | Drawn |
|---|---|---|---|
| 2025 Credit Agreement | $7.50M | $100.00M | – |
| Line of Credit | $200.00M | – | – |
| Line of Credit | $40.00M | – | – |
| Term Loan | $360.75M | – | – |
| Term Loan Facilities | – | – | $250.50M |
See a number that looks wrong?